About Polyplus Transfection
Polyplus Transfection is a company based in Illkirch-graffenstaden (France) founded in 2001 was acquired by Sartorius in March 2023.. Polyplus Transfection has raised $3.23 million across 2 funding rounds from investors including Sartorius, CIC and Warburg Pincus. Polyplus Transfection has completed 2 acquisitions, including Bio Elpida and Xpress Biologics. Polyplus Transfection offers products and services including FectoVIR, PEIpro, in vivo-jetRNA, FectoPRO, and jetOPTIMUS. Polyplus Transfection operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Illkirch-graffenstaden, France
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$3.23 M (USD)
in 2 rounds
-
Latest Funding Round
$3.23 M (USD), Series A
Jan 10, 2011
-
Investors
Sartorius
& 9 more
-
Employee Count
Employee Count
-
Investments & Acquisitions
Bio Elpida
& 1 more
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Polyplus Transfection
Polyplus Transfection offers a comprehensive portfolio of products and services, including FectoVIR, PEIpro, in vivo-jetRNA, FectoPRO, and jetOPTIMUS. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
For large scale rAAV manufacturing processes
Leader for viral vector production in various scales
For in vivo mRNA delivery using lipid nanoparticles
For high-yield protein expression in cell systems
For efficient DNA transfection in hard-to-transfect cells
Funding Insights of Polyplus Transfection
Polyplus Transfection has successfully raised a total of $3.23M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $3.23 million completed in January 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $3.2M
-
First Round
First Round
(09 Dec 2009)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2011 | Amount | Series A - Polyplus Transfection | Valuation |
investors |
|
| Dec, 2009 | Amount | Debt – Convertible - Polyplus Transfection | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Polyplus Transfection
Polyplus Transfection has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Sartorius, CIC and Warburg Pincus. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Growth and acquisition investments are managed by Credit Mutuel Equity.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Polyplus Transfection
Polyplus Transfection has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Bio Elpida and Xpress Biologics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
CRO offering recombinant protein and antibody related services for preclinical and clinical applications
|
2014 | ||||
|
Bio Elpida, a Biotechnology Contract Manufacturing Company for pre-clinical and clinical development of cell therapy products and bio-products
|
2009 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Polyplus Transfection
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Polyplus Transfection Comparisons
Competitors of Polyplus Transfection
Polyplus Transfection operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Polyplus Transfection
Frequently Asked Questions about Polyplus Transfection
When was Polyplus Transfection founded?
Polyplus Transfection was founded in 2001 and raised its 1st funding round 8 years after it was founded.
Where is Polyplus Transfection located?
Polyplus Transfection is headquartered in Illkirch-graffenstaden, France. It is registered at Illkirch-graffenstaden, Bas-rhin, France.
Is Polyplus Transfection a funded company?
Polyplus Transfection is a funded company, having raised a total of $3.23M across 2 funding rounds to date. The company's 1st funding round was a Debt – Convertible of $1.78M, raised on Dec 09, 2009.
What does Polyplus Transfection do?
Polyplus Transfection is a biotechnology company that develops and sells innovative solutions for in vivo, in vitro and ex vivo delivery of nucleic acids in research, bioproduction and therapeutics. Supplies its proprietary range of reagents for the transfection of genes, oligonucleotides and siRNA through a global distributor network for use in clinical trials. Also holds a broad estate of patents and licenses including original methods for therapeutic siRNA delivery. Products include - jetPRIME, INTERFERin, FectoPRO, PEIpro for in-vitro; in vivo-jetPEI, cGMP grade in vivo-jetPEI, jetSI 10 mM for in vivo; and others like Zip Nucleic acid (ZNA for Molecular Biology Diagnostics), STICKY SIRNA (for Therapeutic siRNA), OLIGOPLUS and SIRNAPLUS (for Therapeutic cationic Oligonucleotides), Personalized transfection services (for Transfection optimization) and Custom-made products (for in vitro transfection, therapeutics).
Who are the top competitors of Polyplus Transfection?
Polyplus Transfection's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
What products or services does Polyplus Transfection offer?
Polyplus Transfection offers FectoVIR, PEIpro, in vivo-jetRNA, FectoPRO, and jetOPTIMUS.
How many acquisitions has Polyplus Transfection made?
Polyplus Transfection has made 2 acquisitions, including Bio Elpida, and Xpress Biologics.
Who are Polyplus Transfection's investors?
Polyplus Transfection has 10 investors. Key investors include Sartorius, CIC, Warburg Pincus, Crédit Mutuel Equity, and Banque de Vizille.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.